Assessment of type I interferon response in routine practice in France in 2022
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
An European Alliance of Associations for Rheumatology task force recently recommended specific points to consider for exploring type I interferon pathway in patients, highlighting the lack of analytical assays validated for clinical routine. We report here the French experience on a type I interferon pathway assay that has been set up and used routinely since 2018 in Lyon, France.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
RMD open - 9(2023), 2 vom: 01. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nombel, Anais [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoimmune Diseases |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 11.12.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1136/rmdopen-2023-003211 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358232554 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358232554 | ||
| 003 | DE-627 | ||
| 005 | 20231227131327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/rmdopen-2023-003211 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM358232554 | ||
| 035 | |a (NLM)37321666 | ||
| 035 | |a (PII)e003211 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nombel, Anais |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of type I interferon response in routine practice in France in 2022 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 11.12.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a An European Alliance of Associations for Rheumatology task force recently recommended specific points to consider for exploring type I interferon pathway in patients, highlighting the lack of analytical assays validated for clinical routine. We report here the French experience on a type I interferon pathway assay that has been set up and used routinely since 2018 in Lyon, France | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autoimmune Diseases | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Dermatomyositis | |
| 650 | 4 | |a Lupus Erythematosus, Systemic | |
| 650 | 7 | |a Interferon Type I |2 NLM | |
| 700 | 1 | |a Foray, Anne Perrine |e verfasserin |4 aut | |
| 700 | 1 | |a Garnier, Lorna |e verfasserin |4 aut | |
| 700 | 1 | |a Lombard, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Hachulla, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Bader-Meunier, Brigitte |e verfasserin |4 aut | |
| 700 | 1 | |a Georgin-Lavialle, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Melki, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Walzer, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Belot, Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Viel, Sebastien |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t RMD open |d 2015 |g 9(2023), 2 vom: 01. Juni |w (DE-627)NLM254089658 |x 2056-5933 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:2 |g day:01 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/rmdopen-2023-003211 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 2 |b 01 |c 06 | ||